がん治療ワクチン：目前の成功

Abstract

The authors combine expertise in market development with direct experience in cancer vaccine development to provide a concise analysis of this market including the current trends, and market forecast. This Report provides a comprehensive analysis of therapeutics currently in development, as well as those that have been discontinued. Development strategies are also discussed in detail. Primary market research was utilized to elucidate the opinions of cancer vaccine developers, and responses from these experts are included throughout the Report.

TABLE OF CONTENTS

Chapter 1: Executive Summary

• References

Chapter 2: Introduction

• Historical Perspective
• Basic Immunological Principles Discussed in This Report
• Intermediate Immunological Principles Discussed in This Report
• References

Chapter 3: Assessment of the Current State of Therapeutic Development

• Reasons for Pessimism
• Reasons for Optimism
• References

Chapter 4: Development Strategies

• Antigen Selection
  • In Search of the Ideal Antigen
• Common Antigens in Cancer Vaccines
  • Complex Antigen Cocktails: Autologous versus Allogeneic
• Current Development Strategies
• Adjuvants
  • Late-stageLate- Stage Clinical Development
  • Phase I and Preclinical
  • Halted
• Peptides
  • Late-Stage Clinical Development
  • Phase I and Preclinical
  • Halted
• Plasmid DNA and Viral Vectors
  • Late-Stage Clinical Development
  • Phase I and Preclinical
  • Halted
• Microbial Vectors
  • Phase I and Preclinical
• Tumor Cells
  • Late-Stage Clinical Development
  • Phase I and Preclinical
  • Halted
• Dendritic Cells (DCs)
  • Late-Stage Clinical Development
  • Phase I and Preclinical
  • Halted
• Other Strategies
  • Late-Stage Clinical Development
  • Phase I and Preclinical
  • Halted
• Future Strategies
  • Maintenance
  • Removing Inhibition in the Local Tumor Environment
  • Activating The Innate System
• Clinical Trials
• Surrogate Markers
• Standardizing and Combining Trials
  • Trials in the Sickest of the Sick
• Market Model
  • Methodology and Assumptions
  • Forecast
• References
• Endnotes

Chapter 5: Company Pro.les

• Anosys, Inc.
• Antigenics Inc.\
• Argos Therapeutics, Inc.
• AVAX Technologies, Inc.
• Biomira Inc. . 5・6
• CancerVax Corporation
• Cerus Corporation
• Corixa Corporation
• Cytogen Corporation
• Dendreon Corporation
• Enzo Biochem, Inc.
• Favrille, Inc.
• Genitope Corporation
• Genzyme Corporation
• IDM S.A.
• Immune Response Corporation
• Juvaris BioTherapeutics, Inc.
• Medarex, Inc.
• NEMOD Biotherapeutics GmbH & Co. KG
• Northwest Biotherapeutics, Inc.
• NovaRx Corporation
• Oxxon Therapeutics Inc.
• Therion Biologics Corporation
• Transgene S.A.
• Vical Inc.

TABLE OF EXHIBITS

• Exhibit 3.1 Cancer Vaccines in Phase III Clinical Trials
• Exhibit 3.2 Cancer Vaccines in Phase II Clinical Trials
• Exhibit 3.3 Survey Question: How would you rank the following criteria in importance?
• Exhibit 3.4 Results of Clinical Vaccine Studies in Patients with Metastatic Cancers
• Exhibit 4.1 Survey Question: How do you rank the following challenges in developing therapeutic cancer vaccines?
• Exhibit 4.2 Examples of Tumor Antigens
• Exhibit 4.3 Survey Question: Please rank the following development strategies as to which you think is the most likely to succeed (adapted from Berzofsky, et al.)
• Exhibit 4.4 Survey Question: What are the most promising methods for improving cancer immunotherapeutics?
• Exhibit 4.5 Technologies for Monitoring Immune Responses
• Exhibit 4.6 Survey Question: Which of the following therapeutic vaccines currently in Phase III do you think is most likely to succeed?
• Exhibit 4.7 Projected U.S. Market for Therapeutic Vaccines